Sugemalimab

EQRx Announces Partnership Agreement with Abdul Latif Jameel Health to Commercialize Lead Oncology Programs in Middle East, Turkey and Africa

Retrieved on: 
Monday, November 22, 2021

Through the agreement, Abdul Latif Jameel Health will become EQRxs regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.

Key Points: 
  • Through the agreement, Abdul Latif Jameel Health will become EQRxs regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.
  • Its our joint mission with EQRx to change that, a mission that is aligned with the values of the Jameel Family.
  • Aumolertinib is a novel, irreversible EGFR-TKI that selectively inhibits both EGFR sensitizing and resistance mutations with high selectivity over wild-type EGFR.
  • EQRx and Remaking Medicine are trademarks of EQRx, Inc.
    1World Health Organization, International Agency for Research on Cancer.

EQRx and NHSE Sign Memorandum of Understanding to Enter into England’s First Population Health Partnership for Cancer Drugs

Retrieved on: 
Tuesday, October 19, 2021

Launched in January 2021, the Innovation Passport aims to accelerate treatment through regulatory approval and reimbursement as part of the ILAP.

Key Points: 
  • Launched in January 2021, the Innovation Passport aims to accelerate treatment through regulatory approval and reimbursement as part of the ILAP.
  • The process is also supported by additional bodies including the NHS England, the NHS Improvement, Health Research Authority and the National Institute for Health Research.
  • EQRx holds the development and commercialization rights to aumolertinib outside of Greater China and is pursuing regulatory discussions in multiple countries.
  • In August 2021, EQRx announced a proposed combination with CM Life Sciences III (Nasdaq: CMLTU) to accelerate its growth.

EQRx Announces Presentation of Phase 3 Data Demonstrating a Progression-Free Survival Benefit with Sugemalimab Consolidation Therapy in Patients with Stage III NSCLC at ESMO Congress 2021

Retrieved on: 
Friday, September 17, 2021

GEMSTONE-301 is the first positive Phase 3 trial of a PD-(L)1 agent in this broad Stage III NSCLC patient population setting.

Key Points: 
  • GEMSTONE-301 is the first positive Phase 3 trial of a PD-(L)1 agent in this broad Stage III NSCLC patient population setting.
  • Overall survival (OS) data were immature, but an encouraging trend for a survival benefit with sugemalimab vs. placebo was observed with follow-up of patients ongoing.
  • These data suggest sugemalimab may have the potential to treat a broad population of patients with Stage III NSCLC.
  • The upcoming presentation at ESMO 2021 in Stage III NSCLC builds upon the recent presentation of updated data from the GEMSTONE-302 study in Stage IV NSCLC at the IASLC 2021 World Conference on Lung Cancer, positioning sugemalimab as a potential treatment option to address both Stage III and IV NSCLC.

EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC

Retrieved on: 
Tuesday, September 14, 2021

GEMSTONE-302 is a placebo-controlled Phase 3 trial evaluating the efficacy and safety of the anti-PD-L1 antibody sugemalimab in combination with chemotherapy as a first-line treatment for patients with Stage IV non-small cell lung cancer (NSCLC).

Key Points: 
  • GEMSTONE-302 is a placebo-controlled Phase 3 trial evaluating the efficacy and safety of the anti-PD-L1 antibody sugemalimab in combination with chemotherapy as a first-line treatment for patients with Stage IV non-small cell lung cancer (NSCLC).
  • We look forward to more mature OS data from GEMSTONE-302 as well as continued regulatory discussions for sugemalimab in multiple countries.
  • Details of the presentation are as follows:
    Session: MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?
  • Subgroup analysis showed clinical benefit regardless of PD-L1 expression level or pathologic subtype in patients with Stage IV NSCLC.

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

Retrieved on: 
Wednesday, September 30, 2020

During Phase 1a and 1b stages of the study, sugemalimab showed antitumor activity in multiple tumor types and was well-tolerated.

Key Points: 
  • During Phase 1a and 1b stages of the study, sugemalimab showed antitumor activity in multiple tumor types and was well-tolerated.
  • CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide.
  • At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life.
  • For more than 170 years, Pfizer has worked to make a difference for all who rely on us.